Conference Schedule / Thursday May 3, 2012

7:30-8:30  Breakfast and Registration (2nd Level, Grand Banking Hall)

8:30-8:45  Welcome and Introduction
Michael Sherar, President & CEO, Cancer Care Ontario
David Jaffray, Acting Chair, UT DRO

8:45-9:30  Keynote Address
Growth and Acceptance of SBRT for Treatment of Primary and Metastatic Cancers
Paul Okunieff
Objectives: After this session, the attendees will be able to
• discuss staging metastases in defining new clinical trials.
• define evidence of oligometastases.
• discuss historical successes of local treatments for control of metastases.

9:30-9:45  Question and Answer Period

9:45-10:15  Break

10:15-11:45  Session 1 – Lung Cancer
Moderator: Patrick Cheung
Objectives: After this session, the attendees will be able to
• evaluate clinical outcomes related to and discuss the technical aspects of delivering SBRT in lung cancers.
• discuss the need for quality assurance and apply standards of care when adopting new treatment techniques.

  10:15-10:35  Should SBRT be the Standard of Care for Medically Inoperative Early Stage Lung Cancer?
David Palma

  10:35-10:45  Question and Answer Period

  10:45-11:05  Technologic Advances in Lung SBRT
Jean-Pierre Bissonnette

  11:05-11:15  Question and Answer Period

  11:15-11:35  Should there be Provincial Guidelines Regarding the Use of SBRT?
Patrick Cheung

  11:35-11:45  Question and Answer Period

11:45-1:15  Lunch
Conference Schedule / Thursday May 3, 2012

1:15-2:45  Session 2 – Prostate Cancer

Moderator: Michael Sharpe

Objectives: After this session, the attendees will be able to
• compare and contrast clinical outcomes related to the use of SBRT and HDR Brachytherapy in prostate cancer.
• discuss the technical aspects of delivering HDR Brachytherapy for prostate cancer.

1:15-1:35  HDR or LDR Brachytherapy for Prostate Cancer?
Gerard Morton

1:35-1:45  Question and Answer Period

1:45-2:05  SBRT: Is this the Future of Radiotherapy for Prostate Cancer?
Andrew Loblaw

2:05-2:15  Question and Answer Period

2:15-2:35  Physics Issues in HDR Prostate Brachytherapy
Ananth Ravi

2:35-2:45  Question and Answer Period

2:45-3:15  Break

3:15-4:45  Session 3 – Liver and Spine

Moderator: Nicole Harnett

Objectives: After this session, the attendees will be able to
• evaluate clinical outcomes related to the use of SBRT in the treatment of paraspinal and liver disease.
• articulate the benefits of significant hypofractionation in these patients.
• discuss the technical challenges of delivering SBRT to these sites.

3:15-3:35  SBRT for Spinal Metastases: How, When and Why?
Arjun Sahgal

3:35-3:45  Question and Answer Period

3:45-4:05  Tumour Motion Management for Liver SBRT
Michael Velec

4:05-4:15  Question and Answer Period

4:15-4:35  The Emerging Role of Stereotactic Body Radiotherapy in the Management of Colorectal Liver Metastases
William Chu

4:35-4:45  Question and Answer Period

4:45-6:00  Poster Viewing and Reception (3rd Level, King Gallery)
Conference Schedule / Friday May 4, 2012

7:30-8:30  Breakfast and Registration

8:30-8:45  Welcome and Introduction
Patrick Cheung, Co-Chair, Organizing Committee, UT DRO

8:45-9:30  Keynote Address
MR Brachytherapy for Cervical Cancer
Kari Tanderup
Objectives: In this session, the attendees will be able to
• explain the principles of image-guided brachytherapy in cervix cancer.
• discuss upcoming data from clinical trials on image guided brachytherapy.

9:30-9:45  Question and Answer Period

9:45-10:15  Break

10:15-11:45  Session 4 – Gynecologic Cancer
Moderators: Ida Ackerman, Michael Milosevic
Objectives: After this session, the attendees will be able to
• evaluate clinical outcomes related to Brachytherapy for gynecological cancers.
• describe the uncertainties and controversies inherent in delivering Brachytherapy for cervical cancer.
• discuss various approaches to quality assurance and developing standards of care when adopting new treatment techniques.

10:15-10:35  Guidelines and Standards for Cervical Cancer Brachytherapy
Anthony Fyles

10:35-10:45  Question and Answer Period

10:45-11:05  Interstitial Brachytherapy for Cervical Cancer
David D’Souza

11:05-11:15  Question and Answer Period

11:15-11:35  Panel: Cases and Controversies in Image-Guided Brachytherapy for Cervical Cancer
Panelists: Kari Tanderup, Anthony Fyles, David D’Souza

11:35-11:45  Question and Answer Period

11:45-1:15  Lunch
Conference Schedule / Friday May 4, 2012

1:15-2:45  Session 5 – Biologic Insights
Moderator: Lori Holden
Objectives: After this session, the attendees will be able to
• identify radiobiological mechanisms at work when significant hypofractionation is used.
• describe methods for exploiting biological and molecular characteristics to improve the therapeutic ratio in radiation therapy.

1:15-1:35  The Biology of Hypofractionated Radiotherapy
Bradly Wouters

1:35-1:45  Question and Answer Period

1:45-2:05  Multiparametric MR-Imaging of Tumour Biology to Guide Prostate Cancer Radiotherapy
Cynthia Ménard

2:05-2:15  Question and Answer Period

2:15-2:35  Personalized Treatment of Brain Tumours: Integrating Radiotherapy and Molecular Therapeutics
Caroline Chung

2:35-2:45  Question and Answer Period

2:45-3:15  Break

3:15-4:15  Session 6 – Thoughts from the Trenches
Moderator: Miller MacPherson
Objectives: After this session, the attendees will be able to
• appreciate the realities of new program development and the challenges that must be addressed when implementing new programs/approaches.

3:15-3:30  Timelines and Efficiency of MR-guided Brachytherapy for Cervical Cancer
Kitty Chan

3:30-3:35  Question and Answer Period

3:35-3:50  Lung SBRT in Mississauga: Tips for Starting a New Program
Hany Soliman

3:50-3:55  Question and Answer Period

3:55-4:10  CyberKnife Radiosurgery: A Different Approach to IGRT
Martin Shim

4:10-4:15  Question and Answer Period
Conference Schedule / Friday May 4, 2012

4:15-5:00  Debate

*Be it Resolved that HDR Brachytherapy Should be the Standard of Care in Ontario for Men with Intermediate Risk Prostate Cancer.*

For: Charles Catton
Opposed: Gerard Morton

Objectives: After this session, the attendees will be able to
• evaluate clinical outcomes related to the use of SBRT and HDR Brachytherapy for prostate cancers.
• emphasize the need for quality assurance and apply standards of care when adopting new treatment techniques.

5:00  Wrap Up

Patrick Cheung, Co-Chair, Organizing Committee, UT DRO